secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0001558370-25-011885
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio FY2025 revenue $0.4M, cash $8.8M; advances obesity pipeline with IBIO-610 fat loss data
--------------------------------------------------------------------------------

- Revenue $0.4M (up $0.2M YoY); R&D expense $8.3M (+$3.1M); G&A $10.7M (-$1.0M).
- Cash $8.8M at June 30; raised $6.2M warrant inducement; closed $50M public offering (potential +$50M on warrant exercise).
- IBIO-610 (activin E) showed 26% fat mass reduction with no lean mass loss in mice; NHP study initiated.
- IBIO-600 (anti-myostatin) NHP PK data demonstrated extended half-life and dose-dependent muscle growth.
- Collaboration with AstralBio yielded amylin receptor antibody reducing acute food intake 60% in obese mice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000155837025011885/0001558370-25-011885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000155837025011885/ibio-20250905x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer